UN warns about chances of developing a second cancer after radiotherapy

Cancer survivors often worry about developing a second primary cancer – a new and separate tumor that appears after the first one has been treated – showing up years after treatment. That fear is understandable, and it deserves facts, not folklore.

A second primary cancer is not a recurrence of the original disease, and it may develop in a different organ for different reasons.

“This evaluation underscores the need to balance the life-saving benefits of radiotherapy, the use of targeted radiation to kill cancer cells, with a clear understanding of its long-term risks. 

It provides the scientific foundation for improving cancer care and guiding international safety standards,” said Dr. Sarah Baatout, Chair of The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR).

What the UN says about second cancer

In its 2024 annex, the UNSCEAR concludes that between 5 and 15 percent of cancer survivors may develop second primary cancers, and that only a small share of those cases are likely to be attributable to radiotherapy. 

The range reflects how tissues at risk and their radiation doses differ across tumor sites and treatment techniques.

A large population-based study of adults treated across U.S. cancer registries estimated that about 8 percent of second solid cancers observed among irradiated patients could be attributed to radiotherapy by 15 years after diagnosis, equal to roughly five extra cases per 1,000 treated. 

The risk tended to be higher in organs that receive higher doses, lower when treatment begins at an older age, and greater the farther out one looks in time.

How radiation therapy helps patients

A widely cited review reports that about half of all people with cancer receive radiation at some point in their care, and that radiation contributes to roughly 40 percent of all cures. 

Radiation works by damaging tumor DNA until cancer cells stop dividing or die, the main objective in both curative and symptom-relieving care.

According to the National Cancer Institute, guidance radiation can be used on its own or with surgery, chemotherapy, or immunotherapy, and it is delivered either from outside the body or by placing radioactive sources inside or near the tumor. 

These choices are tailored to the disease, the patient’s overall health, and how close the tumor lies to sensitive normal tissues. The point is simple and practical. 

When radiation is the best tool to control a cancer or to relieve serious symptoms, skipping it because of a distant risk can trade a real benefit today for a smaller, delayed risk later.

Second cancers and radiation

Second cancers can arise from many causes, including smoking, alcohol use, inherited mutations, hormonal changes, and the natural effects of aging. 

Distinguishing those factors from the impact of treatment is difficult, so UNSCEAR relied on epidemiology and dosimetry to estimate how much of the risk truly stems from radiation exposure during therapy.

Epidemiological analyses compare outcomes between people who received radiation and those who did not, while dosimetry tracks how much radiation each organ absorbs during a treatment course. 

Neither approach captures every detail of a person’s life, but together they provide more reliable and less biased estimates of treatment-related risk.

The key takeaway is clear: most second cancers in survivors are not caused by radiotherapy.

That does not mean the risk is zero, but rather that the added risk from radiation is small compared with other long-term factors that contribute to cancer over a lifetime.

Second cancer risk groups

NCI resources show that risk is not uniform, and it changes with age at treatment, the organs exposed, genetic predispositions, and the time since therapy. 

Survivors treated as children carry higher lifetime windows of opportunity for a second cancer to appear, and some inherited syndromes heighten sensitivity to radiation.

Some tissues are more vulnerable than others. The thyroid, breast, and brain in younger patients tend to be especially sensitive, while older adults have less time for radiation-related cancers to develop, reducing lifetime risk even when short-term hazards appear similar.

Previous treatments also influence risk. Combinations involving certain chemotherapies, higher doses to larger areas, or repeated exposure can push the numbers upward, so treatment plans are designed to limit radiation to sensitive organs whenever possible.

How modern planning limits risk

Modern techniques that shape and guide radiation beams help protect healthy tissue, while advanced imaging allows teams to target tumors with greater precision. 

These measures do not eliminate risk, but they reduce exposure to surrounding areas, and that reduction matters most for preventing future cancers.

Comparative research shows that technology choices can affect the likelihood of second cancers. 

In a national database analysis covering hundreds of thousands of patients, proton beam radiation was linked to a lower chance of second cancers than an alternative form of advanced radiotherapy that uses computer-controlled beams called intensity-modulated radiation therapy. 

The adjusted odds ratio was 0.31, though researchers note that follow-up time and patient selection still influence these results.

All of this reflects an honest trade-off. When a treatment plan cures the original cancer or extends life with fewer side effects, accepting a small long-term risk of a second cancer can be worthwhile. Clinicians continue refining techniques to make that small risk even smaller.

What this means for decisions today

The UNSCEAR message is not an invitation to be casual. It is a call to personalize care, to monitor survivors over time, and to keep improving methods so that normal tissues see less dose without compromising control of the first cancer.

For patients, the practical steps are straightforward. Ask which nearby organs are most sensitive, how the plan limits dose to them, and whether alternatives like different beam arrangements or schedules could reduce exposure while preserving the chance of cure.

For clinicians and planners, the work continues. Use dose constraints backed by data, document the exposure to organs at risk, and share follow up recommendations that match the patient’s age, tumor site, and prior treatments so that any new problem is caught early rather than late.

Bottom line for fear and facts

Fear can be loud, but numbers can speak for themselves. Most second cancers in survivors are not caused by radiotherapy, and when radiation is indicated for the first cancer, the benefit usually outweighs the small added risk.

That risk is not ignored, it is managed. Teams use imaging, plan optimization, and careful field design to protect healthy tissues, and they revisit survivors in the years after treatment to catch problems before they grow.

The UNSCEAR assessment does not minimize risk, it puts it in perspective. It supports choosing the right plan for the right patient, then following through with long term care that respects both the win today and the responsibility for tomorrow.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–